UK Medicines Information
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Information type:
Randomised controlled trials
Source:
Lancet Public Health
Specialities:
Cardiovascular system disorders
Summary
In this study, an ultrathin strut biodegradable polymer sirolimus-eluting stent (Orsiro) was non-inferior to a thin strut durable polymer everolimus-eluting stent (Xience Prime/Xpedition) for target lesion failure in a population with high adherence to dual antiplatelet therapy.
UKMi comment
A Comment article discussing this research is available via the link below.
Related links:
Comment